Catalog No.
DHD62601
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Human
Isotype
IgG4-kappa
Clonality
Monoclonal
Target
IL-4RA, IL-4-binding protein, IL-4 receptor subunit alpha, Soluble IL-4R-alpha, IL4-BP, IL4R, IL-4R subunit alpha, IL-4R-alpha, CD124, Interleukin-4 receptor subunit alpha, IL4RA, Soluble IL-4 receptor subunit alpha, sIL4Ralpha/prot
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P24394
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
CD124, REGN668, SAR231893, CAS: 1190264-60-8
Clone ID
Dupilumab
Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma, PMID: 29782217
Dupilumab for treatment of atopic dermatitis, PMID: 29557246
Mechanisms of Dupilumab, PMID: 31505066
Dupilumab: A review of its use in the treatment of atopic dermatitis, PMID: 29471919
Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials, PMID: 31543428
Dupilumab for the treatment of asthma, PMID: 28085503
Dupilumab treatment in adults with moderate-to-severe atopic dermatitis, PMID: 25006719
Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial, PMID: 28478972
Management of dupilumab-associated conjunctivitis in atopic dermatitis, PMID: 30873757
Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis: A Phase 3 Randomized Clinical Trial, PMID: 31693077
Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma, PMID: 29782224
Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: A randomized, double-blinded, placebo-controlled phase 3 trial, PMID: 32574587
Dupilumab for atopic dermatitis: evidence to date, PMID: 31210470
Dupilumab: Basic aspects and applications to allergic diseases, PMID: 32007360
Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis, PMID: 30194992
Dupilumab: A New Paradigm for the Treatment of Allergic Diseases, PMID: 29939132
Conjunctivitis in dupilumab clinical trials, PMID: 30851191
Dupilumab for prurigo nodularis: Case series and review of the literature, PMID: 31917498
Dupilumab and COVID-19: What should we expect?, PMID: 32362061
Dupilumab to Treat Type 2 Inflammatory Diseases in Children and Adolescents, PMID: 32157553
Real-world evidence of dupilumab efficacy and risk of adverse events: A systematic review and meta-analysis, PMID: 32822798
Dupilumab: A Review in Chronic Rhinosinusitis with Nasal Polyps, PMID: 32240527
Dupilumab use in dermatologic conditions beyond atopic dermatitis - a systematic review, PMID: 31693426
Efficacy of Dupilumab in a Phase 2 Randomized Trial of Adults With Active Eosinophilic Esophagitis, PMID: 31593702
Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study, PMID: 31374300
Dupilumab Efficacy in Patients with Uncontrolled, Moderate-to-Severe Allergic Asthma, PMID: 31521831
Dupilumab in the treatment of chronic rhinosinusitis with nasal polyposis, PMID: 32075470
Dupilumab in the treatment of asthma, PMID: 31218914
Dupilumab in persistent asthma with elevated eosinophil levels, PMID: 23688323
A Clinician's Guide to the Recognition and Management of Dupilumab-Associated Conjunctivitis, PMID: 31728936
Dupilumab (Dupixent) for Asthma, PMID: 32053330
Dupilumab treatment in moderate-to-severe atopic dermatitis: A systematic review and meta-analysis, PMID: 29472119
Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFÉ), PMID: 29193016
Dupilumab for the treatment of adolescents with atopic dermatitis, PMID: 32720530
Dupilumab as a novel therapy for bullous pemphigoid: A multicenter case series, PMID: 32179082
Efficacy and Safety of Multiple Dupilumab Dose Regimens After Initial Successful Treatment in Patients With Atopic Dermatitis: A Randomized Clinical Trial, PMID: 31876900
Dupilumab reduces local type 2 pro-inflammatory biomarkers in chronic rhinosinusitis with nasal polyposis, PMID: 30488542
Real-world persistence with dupilumab among adults with atopic dermatitis, PMID: 32739313
Dupilumab: Clinical Efficacy of Blocking IL-4/IL-13 Signalling in Chronic Rhinosinusitis with Nasal Polyps, PMID: 32440101
IL-4Rα Blockade by Dupilumab Decreases Staphylococcus aureus Colonization and Increases Microbial Diversity in Atopic Dermatitis, PMID: 31252032
Eye Complications During Dupilumab Treatment for Severe Atopic Dermatitis, PMID: 30653240
[Experience of using dupilumab in the treatment of severe asthma], PMID: 33346468
▼Dupilumab for atopic dermatitis, PMID: 29545264
[Key-studies on dupilumab], PMID: 30093077
Dupilumab Provides Favorable Safety and Sustained Efficacy for up to 3 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis, PMID: 32557382
Dupilumab for bullous pemphigoid with intractable pruritus, PMID: 32045153
A review of dupilumab in the treatment of atopic diseases, PMID: 30785362
Dupilumab for the Treatment of Recalcitrant Bullous Pemphigoid, PMID: 30140849
Treatment of Netherton Syndrome With Dupilumab, PMID: 31995125
Dupilumab, severe asthma airway responses, and SARS-CoV-2 serology, PMID: 32767400
For research use only. Not for human or drug use.
